Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centers for Disease Control and Prevention
• Collaborators: Universidad del Valle, Guatemala; University of Alabama at Birmingham
• Treatments: Azithromycin; Rifampin

Criteria

Inclusion Criteria:

• Males and non-pregnant/non lactating females >5 years of age

• One onchocercal nodule in an anatomical position where it can be easily removed surgically

Exclusion Criteria:

• Pregnancy (based on urine pregnancy test)

• Breast-feeding

• Women taking oral contraceptives

• Allergy or other adverse reaction to either medication

• Use of other medications that might interact with rifampin

• Clinical evidence of liver disease (jaundice, swollen abdomen)

• Clinical evidence of chronic disease/alcoholism